

PROPOSAL**On approval of the audited 2022 Financial Statements**

To: The General Meeting of Shareholders 2023.

Pursuant to the Law on Enterprise;

Pursuant to Imexpharm Corporation's Charter;

The Board of Directors (BOD) would like to submit to the General Meeting of Shareholders for approval of the 2022 financial statements of Imexpharm Corporation which has been audited by PwC (Vietnam) Limited.

The audited 2022 financial statements have been disclosed in accordance with regulations on the Company's website, including:

1. Company's profile;
2. Statement of the Board of Management;
3. Independent Auditor's Report;
4. Balance sheet (Form No. B01-DN);
5. Income Statement (Form No. B02-DN);
6. Cash Flow Statement (Form No. B03-DN);
7. Notes to the Financial Statements (Form No. B09-DN).

In which:

Some basic indicators in the audited 2022 financial statements:

No.	Major indicators	Unit	2022	2021
1	Total assets	VND	2,276,943,567,575	2,294,700,255,306
2	Total net revenue and income	VND	1,668,222,793,706	1,290,553,589,170
3	Net revenue	VND	1,643,706,514,646	1,266,596,707,350
4	Profit before tax	VND	291,404,142,440	238,859,092,220
5	Profit after tax	VND	223,540,317,602	189,094,874,963

We would like to seek consideration and approval of the General Meeting of Shareholders. *msl*

Recipients:

- As above
- Filing: Admin

**ON BEHALF OF BOARD OF DIRECTORS
CHAIRMAN**



NGUYỄN QUỐC DINH